Multiple NHS drug approvals secured in 2025 including world-first BVD approval, benefitting thousands of myeloma patients
Key Metric 1
UK's leading myeloma charity working to prevent, treat and help people live well with myeloma through research, advocacy and patient support
Key Metric 2
Funding pioneering research, securing NHS treatment access, supporting patients and carers, and raising awareness of myeloma symptoms and precursor conditions
Key Metric 3
IsaVRD quadruplet treatment approved in England, Wales and Scotland — 63% of patients still in remission after five years in trials